Avapritinib, also known as BlU-285, is a potent and selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants and is being developed as a highly targeted therapy for SM, a disorder of the mast cells in which a KIT Exon 17 mutation is the primary driver of disease. BLU-285 is currently being developed by Blueprint.
台州市科瑞生物技术有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
crene